BioVacSafe Project BioVacSafe Project

Welcome to BioVacSafe Project

BioVacSafe - Biomarkers for enhanced vaccines immunosafety - is a 5 years project funded by Innovative Medicine initiative (IMI).

The goal of BioVacSafe is to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market. By  bringing  together for the first time three of Europe's  leading  vaccine  development  and manufacture companies as well as top experts from academic institutions and small and medium-sized enterprises (SMEs),  the project will ultimately accelerate the development and introduction of a new generation of safer, more effective vaccines. By sharing their expertise, the BioVacSafe partners have a unique opportunity to make progress in this important area.

Project Description

On March 1st 2012 the IMI-JU funded project – Biomarkers for Enhanced Vaccine Safety (BioVacSafe) – initiated its collaborative work to develop new tools that will improve the evaluation and monitoring of vaccine immunosafety.

BioVacSafe is a public private consortium of 19 partners involving three of Europe's leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO) actors.

The total budget of the project is 30.2 millions of Euros and it will last for five years.

Read more

Follow us:

facebook twitter linkedin

Project Objectives

The overall objective of the project is to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market.

The three specific objectives of the project are:

• the characterization of early inflammation induced by vaccines currently on the market and the identification and validation of biomarkers of early inflammation and allergic responses;

• the identification and validation of early biomarkers of autoimmunity and their use to help identifying population at risk of developing autoimmunity;

• the analysis of the incidence and epidemiology of autoimmune disease in the general population and the link to genetic background or previous events in the life of patients, including severe effects, such as anaphylactic shock.

 

BioVacSafe Meetings BioVacSafe Meetings

Second BioVacSafe annual meeting

20 - 21 March 2014

The second  BioVacSafe annual meeting will take place on March 20th-21st 2014 at  NOVARTIS VACCINES AND DIAGNOSTICS RESEARCH CENTER, via Fiorentina 1, Siena, Italy.

Here you can dowload the final agenda.

Here you can dowload the schedule of the meeting with some logistic useful information


News News

University of Surrey to Open School of Veterinary Medicine on October 25th 2012

University of Surrey to Open School of Veterinary Medicine on October 25th 2012 The University of Surrey, Guildford, UK announced its plans to open a new School of Veterinary Medicine....

Events Events

World Vaccine Congress Asia 2014

World Vaccine Congress Asia 2014 9-12 June 2014  World Vaccine Congress Asia...

New Horizons for Vaccine Research and Innovation

New Horizons for Vaccine Research and Innovation 12-13 March 2014  New Horizons...

Biomarkers & Diagnostics World Congress 2014

Biomarkers & Diagnostics World Congress 2014 April 30-May 2, 2014  Biomarkers...

Biomarker Summit 2014

Biomarker Summit 2014 March 19-21, 2014  Biomarker Summit 2014 , San Diego, CA. ...

7th Vaccine & ISV Congress

7th Vaccine & ISV Congress 27-29 October 2013 7th Vaccine & ISV Congress, Sitges,...